Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Considerations for evaluating the effectiveness and longterm outcome of enzyme replacement therapy in Pompe disease

  • Cheon, Chong Kun (Department of Pediatrics, Pusan National University Children's Hospital)
  • Received : 2018.12.31
  • Accepted : 2019.07.31
  • Published : 2020.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr 2004;144(5 Suppl):S35-43. https://doi.org/10.1016/j.jpeds.2004.01.053
  2. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148:671-6. https://doi.org/10.1016/j.jpeds.2005.11.033
  3. Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005;128(Pt 3): 671-7. https://doi.org/10.1093/brain/awh384
  4. Laforet P, Nicolino M, Eymard PB, Puech JP, Caillaud C, Poenaru L, et al. Juvenile and adult-onset acid maltase deficiency in France: genotypephenotype correlation. Neurology 2000;55:1122-8. https://doi.org/10.1212/WNL.55.8.1122
  5. Chen M, Zhang L, Quan S. Enzyme replacement therapy for infantileonset Pompe disease. Cochrane Database Syst Rev 2017;11: CD011539.
  6. Kim MS, Song A, Im M, Huh J, Kang IS, Song J, et al. Clinical and molecular characterization of Korean children with infantile and lateonset Pompe disease: 10 years of experience with enzyme replacement therapy at a single center. Korean J Pediatr 2019;62:224-34. https://doi.org/10.3345/kjp.2018.06968
  7. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7. https://doi.org/10.1164/ajrccm.166.1.at1102
  8. Weisman IM, Zeballos RJ. An integrated approach to the interpretation of cardiopulmonary exercise testing. Clin Chest Med 1994;15: 421-45. https://doi.org/10.1016/S0272-5231(21)01082-0
  9. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001;119:256-70. https://doi.org/10.1378/chest.119.1.256
  10. Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet 2012;160C:40-9. https://doi.org/10.1002/ajmg.c.31319